The effect of an interdisciplinary dermatological-rheumatological consultation on the outcome of patients with Psoriasis with musculoskeletal pain: a prospective, single-center cohort study
Introduction: Psoriatic arthritis (PsA), a disease with complex inflammatory musculoskeletal manifestations, complicates psoriasis in up to 30% of patients. In this study, we aimed to determine the effect of an interdisciplinary dermatological-rheumatological consultation (IDRC) for patients with ps...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2023
|
| In: |
Advances in therapy
Year: 2023, Volume: 40, Issue: 12, Pages: 5243-5253 |
| ISSN: | 1865-8652 |
| DOI: | 10.1007/s12325-023-02667-y |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s12325-023-02667-y
|
| Author Notes: | Jan Alwin von Ahnen, Georg Gross, Christian Lull, Mara Blauth, Bernhard Kraemer, Victor Olsavszky, Jan Leipe, Astrid Schmieder |
| Summary: | Introduction: Psoriatic arthritis (PsA), a disease with complex inflammatory musculoskeletal manifestations, complicates psoriasis in up to 30% of patients. In this study, we aimed to determine the effect of an interdisciplinary dermatological-rheumatological consultation (IDRC) for patients with psoriasis with musculoskeletal symptoms. Methods: This prospective study enrolled 202 patients with psoriasis. Patients with musculoskeletal pain (MSP) (n = 115) participated in an IDRC 12 weeks after enrollment. The outcome was evaluated after 24 weeks. Results: In 12/79 (15.2%) patients seen in the IDRC, the prior diagnosis was changed: eight with a first diagnosis of PsA, four with a diagnosis of PsA rescinded. Treatment was modified in 28% of patients. Significant improvements in Psoriasis Area and Severity Index (PASI) (from 5.3 to 2.0; p < 0.001) and Dermatology Life Quality Index (DLQI) (from 6.7 to 4.5; p = 0.009) were observed. By comparing changes in PASI and DLQI over the study period, an improvement in PASI of 0.7 ± 1.4 points (p = 0.64) and in DLQI of 2.9 ± 1.5 points (p = 0.051) could be attributed to participation in the IDRC. Conclusion: An IDRC of patients with psoriasis with MSP leads to a valid diagnosis of PsA and improvement in quality of life. Based on these results, an IDRC is a valuable and time efficient way for psoriasis patient with MSP to receive optimal care. |
|---|---|
| Item Description: | Veröffentlicht: 28. September 2023 Gesehen am 22.11.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1865-8652 |
| DOI: | 10.1007/s12325-023-02667-y |